Fundz

Renibus Therapeutics reported raising $63.8 Million in an initial SEC Form D filing, from an offering of $73.4 Million

PRIVATEJun 09, 2023

Amount Raised

$63.8 Million

$63.8 Million sold, per SEC Form D (first sale May 25, 2023)

Round Type

Venture

SouthlakeBiotechnologyHealthcareHealth CareMedicalTherapeuticsBiopharma

Who to call at Renibus Therapeutics, and when

A new round usually means Renibus Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Renibus Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Renibus Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Renibus Therapeutics

Location

Southlake, Texas, United States

About

Renibus is a clinical-stage biopharmaceutical company focused on preventing disease progression, protecting against organ damage, and improving outcomes in cardiorenal diseases. Its pipeline includes first-in-class therapies that activate cytoprotective pathways. Lead candidate RBT-1, currently in Phase 2 for cardiac surgery, will enter Phase 3 trials to reduce complications post-cardiothoracic surgery. Other programs include RBT-2 for slowing CKD progression, RBT-3 for preventing cisplatin-induced nephrotoxicity, and RBT-9, an anti-inflammatory compound that showed promise in reducing hospital stays in COVID-19 patients.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Renibus Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsJeff K., Co-Founder, President and COOSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Renibus Therapeutics's next move

See what Strategic adds

Renibus Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.